ArticleThoracic cancer2018

Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.

Takayuki Takeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.